Alpha Genesis provides comprehensive biomarker discovery and validation services to ensure that preclinical findings are fully translatable into clinical applications. Our programs integrate fluid and tissue sampling with multiplex cytokine profiling, flow cytometry, histopathology, proteomics, and next-generation sequencing to identify novel biomarkers and validate established ones under GLP-compliant conditions. By employing longitudinal designs and multi-platform assays, we generate robust datasets that capture disease progression, pharmacodynamic activity, and therapeutic response. Our biomarker validation strategies support FDA and EMA regulatory submissions, offering surrogate endpoints, mechanism-of-action confirmation, and translational bridging data.

 

Beyond validation, we specialize in developing customized biomarker panels tailored to unique therapeutic modalities, including advanced biologics and gene therapies, ensuring that our clients not only meet regulatory expectations but also gain deeper insights into therapeutic impact at both systemic and tissue levels. With rigorous assay reproducibility, advanced analytical capabilities, and seamless integration into larger preclinical programs, Alpha Genesis provides biomarker data that drives regulatory acceptance, accelerates clinical translation, and enhances confidence in study outcomes for even the most complex and innovative therapeutic strategies.